

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lustig et al.

Group Art Unit: 1646

Serial No. 09/163,713

Examiner: Pak, M.

Filed: September 30, 1998

Attorney Docket No. T97-012-1

For: *Nuclear Hormone Receptor Drug  
Screens*

## CERTIFICATE OF TRANSMISSION

I hereby certify that this corr is being transmitted by facsimile to the  
Comm for Patents at (703) 308-0294 on September 12, 2002.

Signature

Richard Aron Osman

AMENDMENTThe Commissioner for Patents  
Washington, DC 20231

Dear Examiner Pak:

Please enter these amendments:

## IN THE CLAIMS

✓ Please cancel claim 76.

## REMARKS

*Amendments*

By interview on 8/29/02, Examiners Pak and Eyler requested: (i) deletion of claim 76; (ii) additional declaratory evidence supporting nonobviousness in view of Heery et al. (1997, Nature 387, 733-36) and Krey et al. (1997, Mol Endocrinol 11, 779-791; and (iii) declaratory evidence supporting use of sensor peptides wherein L1-L3 are hydrophobic amino acids other than leucine.

I. Claim 41 is hereby canceled.

II. We append two additional expert Declarations, one from another world-famous biologist,